Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background And Aims: We evaluated the association between endoscopic outcomes following risankizumab induction and subsequent rates of hospitalization and surgery through 52 weeks of risankizumab (both doses) maintenance therapy in patients with Crohn's disease (CD).
Methods: Patients with moderately to severely active CD and clinical response to 12-week risankizumab induction were rerandomized to continued therapy or drug withdrawal in the phase 3 FORTIFY maintenance trial. Incidence rates (events/100 person-years) of CD-related hospitalization and surgery, and the composite of both, through 52 weeks of maintenance were compared between patients achieving vs not achieving predefined endoscopic outcomes following induction.
Results: Patients who achieved vs did not achieve endoscopic response or remission, or absence of ulcers (ulcer-free endoscopy) after induction had reduced rates of CD-related hospitalization through 52 weeks of risankizumab maintenance (endoscopic response, 1.7 vs 7.9/100 person-years; endoscopic remission, 1.2 vs 6.9/100 person-years; ulcer-free endoscopy, 1.5 vs 6.4/100 person-years; all < .05). No CD-related surgeries were observed through 52 weeks of risankizumab maintenance among patients who achieved vs did not achieve endoscopic outcomes following induction (endoscopic response, 0 vs 3.2/100 person-years; endoscopic remission, 0 vs 2.6/100 person-years; ulcer-free endoscopy, 0 vs 2.4/100 person-years; all = .025). In contrast, patients who received placebo during maintenance had statistically similar rates of CD-related hospitalizations and surgeries regardless of achievement of endoscopic outcomes after induction.
Conclusion: Patients achieving endoscopic outcomes following risankizumab induction experienced less CD-related hospitalizations and surgeries through 52 weeks of maintenance when continuing active therapy. Early treatment success may predict favorable long-term outcomes of disease.
Clinical Registeration Number: ADVANCE (NCT03105128); MOTIVATE (NCT03104413) and FORTIFY (NCT03105102).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11720434 | PMC |
| http://dx.doi.org/10.1016/j.gastha.2024.08.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Research Communication: Combination Therapy of Upadacitinib With Infliximab, Risankizumab, Ustekinumab or Vedolizumab for Refractory Crohn's Disease: A Descriptive Case Series.
Aliment Pharmacol Ther
July 2025
Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Combining two advanced therapies may improve outcomes in Crohn's disease (CD) refractory to monotherapy. We conducted a descriptive case series of 27 patients with CD who initiated combination therapy with upadacitinib and infliximab (n = 1), risankizumab (n = 17), ustekinumab (n = 3) or vedolizumab (n = 6). At 12 weeks, 24 achieved clinical response and 9 achieved steroid-free remission.
View Article and Find Full Text PDFSuccessful Identification and Treatment of Cancer of Unknown Primary Originating From Gastric Cancer Using Comprehensive Genomic Profiling and Immune Checkpoint Inhibitor Therapy: A Case Report.
Cancer Rep (Hoboken)
September 2025
Division of Gastroenterology, Department of Internal Medicine, Asahikawa Medical University, Asahikawa, Japan.
Background: Cancer of unknown primary (CUP) is a challenging malignancy characterized by metastatic tumors with an unidentified primary site, even after extensive pathological and radiographic evaluation. Recent advancements in gene expression profiling and comprehensive genomic profiling (CGP) using next-generation sequencing (NGS) have enabled the identification of potential tissue origins, thereby facilitating personalized treatment strategies. Although most cases of CUP present as adenocarcinomas or poorly differentiated tumors, the treatment remains largely empirical, with limited success from molecularly tailored therapies.
View Article and Find Full Text PDFOne-year efficacy of Dupilumab in sense of smell, nasal polyp score and quality of life in CRSwNP patients: A real-world multicenter study in Brazil.
Braz J Otorhinolaryngol
September 2025
Faculdade de Medicina de Ribeirão Preto - Universidade de São Paulo, São Paulo, SP, Brazil.
Introduction: Chronic rhinosinusitis with nasal polyp (CRSwNP) is a predominant type 2 inflammatory disease, affecting the sense of smell and quality of life. Loss of smell compromises physical and emotional health, creating negative impacts and its treatment in CRSwNP is challenging.
Aim: To present the outcomes of dupilumab in olfactory function, Nasal Polyp Score (NPS) and quality of life in Brazilian patients with severe CRSwNP.
Clinical characteristics and histopathologic features of movable inflammatory laryngeal masses in five dogs.
J Vet Med Sci
September 2025
Laboratory of Veterinary Pathology, School of Veterinary Medicine, Nippon Veterinary and Life Science University.
Information on inflammatory laryngeal masses in dogs remains extremely limited. We aimed to describe the clinical and histopathological features and outcomes of five dogs with bilateral, movable inflammatory laryngeal masses. Stridor was a common clinical sign, followed by dysphonia and snoring, all of which were mild.
View Article and Find Full Text PDFEffects of virtual reality-guided imagery relaxation intervention in improving anxiety among lung cancer patients:A Randomized Controlled Trial.
Asian Nurs Res (Korean Soc Nurs Sci)
September 2025
The Fourth Affiliated Hospital of Hebei Medical University; Address: The Fourth Affiliated Hospital of Hebei Medical University, No. 12 Jiankang Road, Chang'an District, Shijiazhuang City, Hebei Province, 050000, People's Republic of China. Electronic address:
Purpose: To examine the effectiveness of virtual reality (VR)-guided imagery relaxation (VRGI) intervention in reducing anxiety among lung cancer surgery patients.
Methods: A randomized clinical trial was conducted at the Fourth Affiliated Hospital of Hebei Medical University (Shijiazhuang, Hebei, China) to recruit patients scheduled for their first elective endoscopic lung cancer surgery under general anesthesia between December 2023 and March 2024. Patients were randomly assigned in a 1:1 ratio to either the control group, receiving routine treatment and staged care in thoracic surgery, or the experimental group, receiving VRGI intervention in addition to the control group's protocol.